Do analysts recommend INM or CLRB?

Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 298.41%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media favor INM or CLRB?

In the previous week, Cellectar Biosciences had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 3 mentions for Cellectar Biosciences and 2 mentions for InMed Pharmaceuticals. Cellectar Biosciences' average media sentiment score of 1.16 beat InMed Pharmaceuticals' score of 0.93 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer INM or QUCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer INM or QUCY?

In the previous week, Mainz Biomed had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 3 mentions for Mainz Biomed and 2 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.93 beat Mainz Biomed's score of 0.58 indicating that InMed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate LPCN or INM?

Lipocine currently has a consensus price target of $15.00, indicating a potential upside of 497.85%. Given Lipocine's stronger consensus rating and higher probable upside, equities analysts clearly believe Lipocine is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer LPCN or INM?

In the previous week, Lipocine had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.93 beat Lipocine's score of 0.39 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INM or PASG?

Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 178.89%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Does the media prefer INM or PASG?

In the previous week, Passage Bio had 7 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 9 mentions for Passage Bio and 2 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.93 beat Passage Bio's score of 0.81 indicating that InMed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Passage Bio 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SNSE or INM?

Sensei Biotherapeutics currently has a consensus price target of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensei Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

InMed Pharmaceuticals (INM) Competitors

$1.49 -0.06 (-3.87%)

As of 10:13 AM Eastern

Compare

INM vs. CLRB, QUCY, LPCN, PASG, and SNSE

Should you buy InMed Pharmaceuticals stock or one of its competitors? MarketBeat compares InMed Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InMed Pharmaceuticals include Cellectar Biosciences (CLRB), Mainz Biomed (QUCY), Lipocine (LPCN), Passage Bio (PASG), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical products" industry.

How does InMed Pharmaceuticals compare to Cellectar Biosciences?

InMed Pharmaceuticals (NASDAQ:INM) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, Cellectar Biosciences had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 3 mentions for Cellectar Biosciences and 2 mentions for InMed Pharmaceuticals. Cellectar Biosciences' average media sentiment score of 1.16 beat InMed Pharmaceuticals' score of 0.93 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InMed Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.00	-$8.16M	-$2.89	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

InMed Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

Cellectar Biosciences has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 298.41%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Cellectar Biosciences beats InMed Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Mainz Biomed?

InMed Pharmaceuticals (NASDAQ:INM) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

InMed Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.22, indicating that its share price is 122% more volatile than the broader market.

Mainz Biomed has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. Mainz Biomed's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Mainz Biomed	N/A	N/A	N/A

InMed Pharmaceuticals has higher revenue and earnings than Mainz Biomed. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.00	-$8.16M	-$2.89	N/A
Mainz Biomed	$540K	41.92	-$16.21M	-$47.60	N/A

In the previous week, Mainz Biomed had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 3 mentions for Mainz Biomed and 2 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.93 beat Mainz Biomed's score of 0.58 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

20.1% of InMed Pharmaceuticals shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Mainz Biomed beats InMed Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Lipocine?

Lipocine (NASDAQ:LPCN) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

In the previous week, Lipocine had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.93 beat Lipocine's score of 0.39 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 6.4% of Lipocine shares are owned by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

InMed Pharmaceuticals has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	10.44	-$9.63M	-$1.88	N/A
InMed Pharmaceuticals	$4.94M	1.00	-$8.16M	-$2.89	N/A

Lipocine currently has a consensus price target of $15.00, indicating a potential upside of 497.85%. Given Lipocine's stronger consensus rating and higher probable upside, equities analysts clearly believe Lipocine is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InMed Pharmaceuticals has a net margin of -132.87% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

Lipocine has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Summary

Lipocine beats InMed Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Passage Bio?

InMed Pharmaceuticals (NASDAQ:INM) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 178.89%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

InMed Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

InMed Pharmaceuticals has higher revenue and earnings than Passage Bio. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.00	-$8.16M	-$2.89	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

Passage Bio has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Passage Bio	N/A	-150.88%	-59.78%

In the previous week, Passage Bio had 7 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 9 mentions for Passage Bio and 2 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.93 beat Passage Bio's score of 0.81 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Passage Bio	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Passage Bio beats InMed Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:SNSE) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sensei Biotherapeutics has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

Sensei Biotherapeutics currently has a consensus price target of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, InMed Pharmaceuticals had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 2 mentions for InMed Pharmaceuticals and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.87 beat InMed Pharmaceuticals' score of 0.93 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sensei Biotherapeutics	Very Positive
InMed Pharmaceuticals	Positive

Sensei Biotherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

InMed Pharmaceuticals has higher revenue and earnings than Sensei Biotherapeutics. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
InMed Pharmaceuticals	$4.94M	1.00	-$8.16M	-$2.89	N/A

Summary

InMed Pharmaceuticals beats Sensei Biotherapeutics on 8 of the 15 factors compared between the two stocks.

Get InMed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INM vs. The Competition

Export

Metric	InMed Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.98M	$3.02B	$6.80B	$12.55B
Dividend Yield	N/A	1.86%	2.66%	6.16%
P/E Ratio	-0.52	19.44	27.42	25.27
Price / Sales	1.00	352.47	542.60	102.53
Price / Cash	N/A	57.53	48.53	58.59
Price / Book	0.22	4.30	11.00	6.57
Net Income	-$8.16M	$64.45M	$3.57B	$336.82M
7 Day Performance	-3.87%	3.46%	2.69%	2.31%
1 Month Performance	-4.49%	2.45%	1.85%	-0.12%
1 Year Performance	-51.78%	34.15%	36.85%	30.30%

InMed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INM InMed Pharmaceuticals	1.5771 of 5 stars	$1.49 -3.9%	N/A	-52.3%	$4.98M	$4.94M	N/A	10
CLRB Cellectar Biosciences	4.5174 of 5 stars	$2.56 +2.4%	$11.00 +329.7%	-60.9%	$20.45M	N/A	N/A	10	Positive News
QUCY Mainz Biomed	0.3096 of 5 stars	$1.39 -7.0%	N/A	N/A	$20.39M	$537.08K	N/A	30
LPCN Lipocine	3.8319 of 5 stars	$2.45 -3.4%	$15.00 +513.5%	-18.0%	$20.15M	$1.98M	N/A	10
PASG Passage Bio	4.5527 of 5 stars	$5.95 -2.8%	$13.25 +122.8%	-39.0%	$19.09M	N/A	N/A	130	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INM) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InMed Pharmaceuticals (INM) Competitors

INM vs. CLRB, QUCY, LPCN, PASG, and SNSE

How does InMed Pharmaceuticals compare to Cellectar Biosciences?

Summary

How does InMed Pharmaceuticals compare to Mainz Biomed?

Summary

How does InMed Pharmaceuticals compare to Lipocine?

Summary

How does InMed Pharmaceuticals compare to Passage Bio?

Summary

How does InMed Pharmaceuticals compare to Sensei Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InMed Pharmaceuticals (INM) Competitors

INM vs. CLRB, QUCY, LPCN, PASG, and SNSE

How does InMed Pharmaceuticals compare to Cellectar Biosciences?

Does the media favor INM or CLRB?

Which has better valuation and earnings, INM or CLRB?

Which has more volatility and risk, INM or CLRB?

Is INM or CLRB more profitable?

Do analysts recommend INM or CLRB?

Do institutionals & insiders believe in INM or CLRB?

Summary

How does InMed Pharmaceuticals compare to Mainz Biomed?

Which has more risk & volatility, INM or QUCY?

Is INM or QUCY more profitable?

Which has preferable valuation & earnings, INM or QUCY?

Does the media prefer INM or QUCY?

Do institutionals and insiders have more ownership in INM or QUCY?

Do analysts prefer INM or QUCY?

Summary

How does InMed Pharmaceuticals compare to Lipocine?

Does the media prefer LPCN or INM?

Do insiders & institutionals believe in LPCN or INM?

Which has higher valuation & earnings, LPCN or INM?

Do analysts rate LPCN or INM?

Is LPCN or INM more profitable?

Which has more volatility & risk, LPCN or INM?

Summary

How does InMed Pharmaceuticals compare to Passage Bio?

Do analysts rate INM or PASG?

Which has more volatility & risk, INM or PASG?

Which has stronger valuation and earnings, INM or PASG?

Is INM or PASG more profitable?

Does the media prefer INM or PASG?

Do insiders and institutionals hold more shares of INM or PASG?

Summary

How does InMed Pharmaceuticals compare to Sensei Biotherapeutics?

Do insiders & institutionals have more ownership in SNSE or INM?

Is SNSE or INM more profitable?

Do analysts rate SNSE or INM?

Does the media refer more to SNSE or INM?

Which has more volatility and risk, SNSE or INM?

Which has preferable earnings & valuation, SNSE or INM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools